Bayer HealthCare is realigning the structure of its global pharmaceutical R&D organization and the company has outlined its future U.S. pharma site plan. Also, NJ will become the U.S. headquarters for pharmaceuticals. The restructuring follows Bayer’s acquisition of Schering AG, Germany in June 2006 and serves as part of the company’s plan to integrate its operations with Schering AG and Berlex, Inc. (the U.S. subsidiary of Schering AG). Through the realignment, research pro...